Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

03.12.18	Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors (GlobeNewswire)
03.12.18	Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
21.11.18	Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy (GlobeNewswire)
13.11.18	FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
01.11.18	Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting (GlobeNewswire)
01.11.18	Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities (GlobeNewswire)
01.11.18	Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia (GlobeNewswire)
29.10.18	Neue Daten der STAIRWAY-Studie zeigen mögliche längere Wirkdauer für Faricimab von Roche bei neovaskulärer altersbedingter Makuladegeneration (nAMD) (GlobeNewswire)
29.10.18	New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD) (GlobeNewswire)
24.10.18	Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza (GlobeNewswire)
22.10.18	Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer (GlobeNewswire)
22.10.18	Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone (GlobeNewswire)
21.10.18	Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours (GlobeNewswire)
20.10.18	Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer (GlobeNewswire)
17.10.18	Roche mit sehr gutem Wachstum in den ersten neun Monaten 2018 (GlobeNewswire)
17.10.18	Roche reports very strong growth in the first nine months of 2018 (GlobeNewswire)
15.10.18	Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research (GlobeNewswire)
15.10.18	Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
10.10.18	OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis (GlobeNewswire)
10.10.18	OCREVUS (Ocrelizumab) fünf-Jahresdaten zeigen, dass ein früher Therapiebeginn bei schubförmiger und primär progredienter multipler Sklerose das Fortschreiten der Erkrankung reduziert (GlobeNewswire)
09.10.18	Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress (GlobeNewswire)
04.10.18	FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors (GlobeNewswire)
04.10.18	Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 (GlobeNewswire)
03.10.18	Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress (GlobeNewswire)
02.10.18	Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS (GlobeNewswire)
25.09.18	Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer (GlobeNewswire)
24.09.18	Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer (GlobeNewswire)
24.09.18	Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer (GlobeNewswire)
24.09.18	Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid (GlobeNewswire)
18.09.18	Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases (GlobeNewswire)
13.09.18	Roche zum zehnten Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
13.09.18	Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running (GlobeNewswire)
06.09.18	Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) (GlobeNewswire)
30.08.18	Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine (GlobeNewswire)
28.08.18	Änderungen in der Konzernleitung von Roche (GlobeNewswire)
28.08.18	Changes to the Roche Corporate Executive Committee (GlobeNewswire)
20.08.18	China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer (GlobeNewswire)
31.07.18	Roche Purchases Shares in Tender Offer for FMI (GlobeNewswire)
26.07.18	Roche mit sehr guten Ergebnissen im ersten Halbjahr 2018 (GlobeNewswire)
26.07.18	Roche reports very strong performance in the first half of 2018 (GlobeNewswire)
23.07.18	Roche erhält CE-Kennzeichnung für Accu-Chek Solo Mikropumpensystem (GlobeNewswire)
23.07.18	Roche receives CE Mark for its Accu-Chek Solo micropump system (GlobeNewswire)
20.07.18	Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference (GlobeNewswire)
20.07.18	FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease (GlobeNewswire)
19.07.18	Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer (GlobeNewswire)
18.07.18	FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) (GlobeNewswire)
17.07.18	Phase-III-Studie CAPSTONE-2 zeigte, dass Baloxavir marboxil die Symptome bei Grippepatienten mit hohem Komplikationsrisiko reduziert (GlobeNewswire)
17.07.18	Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu (GlobeNewswire)
02.07.18	Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash (GlobeNewswire)
02.07.18	Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter